Investigation on the active ingredient and mechanism of <i>Cannabis sativa</i> L. for treating epilepsy based on network pharmacology

Cannabis sativa L. (cannabis) is a medicinal plant and has been used for many years the treatment of epilepsy (EP), which common neurological disease. This study aimed to investigate mechanism cannabis action in EP, with emphasis on leading compounds, targets pathways. In this study, systematic pharmacology bioinformatics approaches were employed identify active ingredients potential treating EP. Furthermore, network construction, Gene Ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) enrichment analysis, molecular docking elucidate against A total 360 compounds collected work. Among them, 226 116 predicted obtained based absorption, distribution, metabolism excretion (ADME) screening databases, respectively. most cannabinoids. The topological analysis showed that cannabinoid receptor 1, albumin glycogen synthase kinase-3 beta (CNR1, ALB GSK3B) key intense interaction. GO KEGG suggested might produce antiepileptic effects by regulating pathways, including calcium signalling pathway, MAPK GABAergic synapse, etc. Additionally, cannabinol methyl ether (M54) be compound docking. Consequently, holistically illuminates constituents pharmacology, contributes searching development new drugs EP.Supplemental data article available online at https://doi.org/10.1080/13102818.2021.1942208 .